Corcept Therapeutics (NASDAQ: CORT) is engaged in the development and marketing of drugs that regulate the consequences of cortisol in the body. Its work on cortisol has led to the discovery of compounds that may help in the management of many diseases. Corcept’s drug Korlym has been approved to tackle Cushion’s syndrome in adult patients who have glucose intolerance and are not suitable for surgery. Corcept is also involved in the marketing of drugs for the control of serious metabolic and psychiatric disorders.........

Continue Here: http://emerginggrowth.com/investing_today/corcept-therapeutics-banks-on-new-drug/04/04/2013